2010 Highlights U.S. ENLIGHT Ablatherm-HIFU clinical trial completed enrollment in June 2010 and entered two year follow-up phase Lithotripsy division revenues increased 10.2% year-over-year to EUR 16.8 million ( USD 22.2 million ), fueled by innovative lithotripter product line Outstanding
Confirmation of HIFU Position in Expanding Focal Therapy Trend in Prostate Cancer Strong Recognition of EDAP's Expertise in Lithotripsy Innovation LYON, France , March 25, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today positive
LYON, France , March 3, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the details relating to its fourth quarter and full year 2010 results announcement, which will take place on Tuesday, March 29, 2011 , before the opening of the
LYON, France , Feb. 2, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today it has been granted a special temporary reimbursement for Ablatherm-HIFU for the treatment of localized prostate cancer by the French National Authority for Health
LYON, France , Jan. 3, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it entered into agreements with certain holders of its senior debentures and warrants to redeem part of EDAP's outstanding convertible debt and cancel some of
LYON, France , Dec. 7, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today that its Sonolith lithotripter products, including Sonolith i-sys and Sonolith i-move, has been exclusively registered by UGAP, the French Public Purchasing Agency
